New data suggests that adoptive cell therapy is a powerful, targeted way to treat malignant pleural mesothelioma.
Pleural mesothelioma is a deadly cancer of the lining around the lungs. It is caused by asbestos exposure and is notoriously difficult to treat.
Now, a new study suggests that cell therapy may help mesothelioma drug treatments work even better.
What is Adoptive Cell Therapy?
Adoptive cell therapy is a form of immunotherapy. Immunotherapy treatments harness the immune system to help fight cancer. Immunotherapy works alone or in combination with other treatments like chemotherapy or surgery.
Many researchers and doctors believe that immunotherapy is the future of mesothelioma treatment.
This therapy is a more targeted way to deliver these cancer-fighting drugs. It does not affect the whole body. Instead, this therapy is delivered where mesothelioma tumors form.
The goal of adoptive cell therapy is to increase the cancer-killing immune cells in a patient’s bloodstream.
What is Interventional Oncology?
Interventional oncology is a subspecialty of radiology. Clinicians use imaging guidance for localized, non-surgical therapy of solid tumors.
Interventional oncology works very well in partnership with immunotherapy. Clinicians can use cell therapy together with Interventional Oncology to monitor mesothelioma treatment.
Immunotherapy now plays a central role in the study of mesothelioma cancer. Interventional oncology is a new method for treating mesothelioma patients in a minimally invasive manner. It has many unique features that can advance the success of cell therapy.
Adoptive cell therapy is a form of immunotherapy. It increases the number of cancer-killing immune cells in a patient’s bloodstream.
Interventional Oncology uses clinical imaging in non-surgical therapy of mesothelioma tumors. It also works together with cell therapy to monitor mesothelioma treatment.
This concept provides new research opportunities with potential beneficial impacts on mesothelioma patients. Preclinical data for therapy using these two approaches appear promising.
Kimura Y, Ghosn M, Cheema W, Adusumilli PS, Solomon SB, Srimathveeralli G. Expanding the role of interventional oncology for advancing precision immunotherapy of solid tumors. Mol Ther Oncolytics. 2021 Dec 21;24:194-204. https://doi.org/10.1016/j.omto.2021.12.018